Bradley Pharma to market probiotic supplement

- Last updated on GMT

Related tags: Medicine, Chr hansen

New Jersey-based Bradley Pharmaceuticals is to market a new
probiotic product, supplied by Danish probiotics leader Chr.
Hansen, to the North American physicians market.

The product, a blend of four strains of probiotic bacteria developed by Chr Hansen, has a novel delivery system said to ensure safe passage of the probiotic strains through the stomach and maximum potency delivery to the intestinal tract, where its beneficial effect is realized. It also requires no refrigeration and is available in a convenient capsule form.

Bradley​ will market the Flora-Q product through its Kenwood Therapeutics division to the gastroenterology and colorectal physician communities, to be dispensed exclusively by the pharmacist. It will be introduced in the first quarter of 2004.

Recent medical studies reporting the benefits of probiotics have helped spur the rapid growth of this market. Datamonitor estimates that US sales of probiotics exceeded $200 million in 2002, growing at a rate of 13 per cent.

Chr. Hansen has sales of more than $600 million annually.

Bradley added that its Kenwood Therapeutics division, which provides gastroenterology, nutritional and respiratory therapies, will increase its sales force by 40 per cent next year.

Related topics: Markets, Probiotics & prebiotics

Related news

Show more

Related products

show more

Probiotic for Children’s Health: B. subtilis DE111

Probiotic for Children’s Health: B. subtilis DE111

Deerland Probiotics & Enzymes | 01-Apr-2021 | Technical / White Paper

In a 2020 survey parents said they see digestive supplements as allies in keeping their kids healthy physically and mentally in these uncertain times;...

Kaneka DR7™ The Dynamic Probiotic for Gut & Brain

Kaneka DR7™ The Dynamic Probiotic for Gut & Brain

Kaneka Probiotics | 29-Mar-2021 | Technical / White Paper

Did you know that 95% of your body’s serotonin (the neurotransmitter that impacts mood, stress, anxiety and immunity) comes from the gut? Microbiota can...

First Low Dose Resistant Starch (RS2)

First Low Dose Resistant Starch (RS2)

Solnul™ | 24-Mar-2021 | Technical / White Paper

Clinically-proven at doses as low as 3.5 g, Solnul™ is the first low dose resistant starch, effective at 1/10 of the previously documented dosage.

Related suppliers

Follow us

Products

View more

Webinars